Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER‐Medicare investigation
Open Access
- 15 May 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (6) , 3325-3335
Abstract
Purpose: Approximately 5% of men were initially diagnosed with (also referred to as de novo) advanced stage prostate cancer and experience far poorer survival compared to men diagnosed with local or regionally advanced disease. Given the number of new therapies targeting metastatic and castrate‐resistant disease, we sought to describe recent treatment patterns by race for de novo AJCC stage IV prostate cancer.Methods: We used Surveillance, Epidemiology, and End Results (SEER) data linked to Medicare files to identify men aged 66 and older diagnosed in 2004‐2014 with advanced prostate cancer, and examined patterns of treatment among all patients and stratified by race/ethnicity.Results: There were 8828 eligible patients identified, and non‐Hispanic black (NHB) patients were more likely to go without treatment (P < 0.001) compared to non‐Hispanic white (NHW) patients, even after accounting for early mortality and TNM stage. The frequency of nearly all forms of treatment was lower among NHB with the exception of orchiectomy, which was significantly higher (10.1% vs 6.1%, P < 0.001), and the use of the progesterone Megace among Medicare Part D enrollees (24.6% vs 15.0%, P < 0.001).Conclusions: Results from this study of elderly Medicare patients presenting with advanced stage prostate cancer suggest that NHB men are less likely to pursue aggressive treatment options. With the reduction in screening for prostate cancer, presumably tied to USPSTF recommendations, and the increasing incidence of men diagnosed with de novo metastatic disease, understanding drivers of treatment‐related decisions are critical in reducing racial disparities in advanced prostate cancer outcomes.Keywords
Funding Information
- National Institutes of Health (P30CA022453)
This publication has 48 references indexed in Scilit:
- Safety of Megestrol Acetate in Palliating Anorexia-Cachexia Syndrome in Patients with Castration-Resistant Prostate CancerJournal of Korean Medical Science, 2013
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsThe Lancet Oncology, 2009
- Metabolic Complications of Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2009
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous BisphosphonatesJournal of Clinical Oncology, 2009
- Patient Expectation of the Partial Response and Response Shift in Pain ScoreSupportive Cancer Therapy, 2007
- Osteoclast differentiation and activationNature, 2003
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999